dm+d
Unassigned
New Medicines
Chronic spontaneous urticaria
Information
New molecular entity
Novartis
Novartis
Development and Regulatory status
Phase III Clinical Trials
Phase III Clinical Trials
Phase III Clinical Trials
Category
Highly selective, potent Brutons tyrosine kinase (BTK) inhibitor for oral administration [1,2]
The lifetime prevalence of chronic urticaria in the UK is 0.5–1%, but approximately 15% of people experience urticaria at some time in their lives [4].
Chronic spontaneous urticaria
Oral